



DIGITAL TRANSFORMATION AND INDUSTRY 4.0 IN PHARMA MANUFACTURING: THE ROLE OF IOT, AI, AND BIG DATA

Sanket J Soni*¹, Ankit Kumar N Patel²

¹Associate Director, Department of Project and Portfolio Management, Amneal Pharmaceuticals, New Jersey, USA

² Director of Formulation, Department of Formulation R&D, Amneal Pharmaceuticals, New Jersey, USA.

Received: 05 Sept 2024 Revised: 19 Sept 2024 Accepted: 25 Oct 2024

Abstract

The pharmaceutical industry is undergoing a significant transformation driven by the integration of digital technologies, collectively known as Industry 4.0. This shift is redefining how drugs are developed, manufactured, and distributed. Key technologies such as the Internet of Things (IoT), Artificial Intelligence (AI), and big data analytics are at the forefront of this change, enabling smart manufacturing, real-time process optimization, and enhanced supply chain management. IoT facilitates the creation of interconnected production environments where sensors and devices continuously monitor critical parameters, ensuring optimal conditions and predictive maintenance. AI accelerates drug discovery through predictive modeling, automates quality control processes, and employs predictive analytics to enhance maintenance and process improvement. Big data empowers data-driven decision-making, ensures regulatory compliance through comprehensive analysis, and supports the shift toward personalized medicine by enabling customized drug production. Despite the significant benefits, the adoption of these technologies poses challenges, including integration with existing systems, data security concerns, and navigating a complex regulatory landscape. This review explores these technologies' impact on pharmaceutical manufacturing, highlighting successful case studies and best practices. Additionally, it discusses the future directions, including the move towards fully autonomous systems and the importance of collaboration between tech companies, manufacturers, and regulators to drive innovation and ensure compliance. The continued evolution of digital technologies in pharma manufacturing promises to enhance efficiency, reduce costs, and deliver more personalized treatments.

Keywords: Industry 4.0, IoT, AI, Big Data, Pharmaceutical Manufacturing, Smart Factories, Digital Transformation

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2024 Author[s] retains the copyright of this article.



*Corresponding Author

Sanket J Soni

DOI: <https://doi.org/10.37022/jis.v7i4.92>

Produced and Published by
South Asian Academic Publications

Introduction

Digital transformation in the pharmaceutical industry refers to the integration of digital technologies into all areas of drug development, manufacturing, and distribution, fundamentally changing how pharmaceutical companies operate and deliver value to patients [1]. This transformation is driven by the need to enhance efficiency, improve product quality, ensure regulatory compliance, and accelerate time-to-market for new drugs. By adopting digital tools such as IoT (Internet of Things), AI (Artificial Intelligence), and big data analytics, pharmaceutical companies can optimize production processes, reduce costs, and personalize

treatments, improving patient outcomes and staying competitive in a rapidly evolving market [2].

Industry 4.0, often referred to as the fourth industrial revolution, represents a new phase in the industrial revolution that focuses on interconnectivity, automation, machine learning, and real-time data[3]. In pharmaceutical manufacturing, Industry 4.0 integrates cyber-physical systems, IoT, AI, big data, and cloud computing to create "smart factories." These smart factories are characterized by their ability to monitor and control production processes autonomously, allowing for real-time optimization and decision-making. Critical components of Industry 4.0 include intelligent sensors that collect and transmit data, AI algorithms that analyze and optimize production, and advanced robotics that perform precise manufacturing tasks. The adoption of Industry 4.0 in pharma is not just about adopting new technologies but about creating an interconnected, intelligent system that enhances all aspects of pharmaceutical production, from drug discovery to delivery [4].

Pharmaceutical Industry 4.0 marks a significant evolution in how drugs are developed, manufactured, and distributed, driven by the integration of digital technologies into every aspect of the production process. This transformation, often termed the fourth industrial revolution, leverages advanced tools like the Internet of Things (IoT), Artificial Intelligence (AI), big data analytics, and cloud computing to create smart, interconnected manufacturing systems [5,6].

Table 1: summarizing the critical components of Pharmaceutical Industry 4.0:

Component	Description
IoT (Internet of Things)	Enables real-time monitoring and data collection from connected devices and sensors throughout manufacturing, enhancing process control and predictive maintenance.
AI (Artificial Intelligence)	Utilises machine learning and advanced analytics to optimize production, improve quality control, and accelerate drug development and manufacturing decision-making.
Big Data Analytics	Involves processing and analyzing large volumes of data to gain insights into production efficiency, quality assurance, and process optimization.
Cyber-Physical Systems	Integrates physical production processes with digital models, allowing for real-time monitoring and dynamic adjustments to enhance precision and flexibility in manufacturing.
Cloud Computing	Provides the infrastructure for storing and analyzing data, facilitating collaboration and integration across different departments and locations.

2. Purpose and Scope of the Review

The primary aim of this review is to examine the transformative impact of the Internet of Things (IoT), Artificial Intelligence (AI), and big data on the pharmaceutical manufacturing industry. These digital technologies are increasingly integrated into manufacturing processes, revolutionizing how drugs are developed, produced, and delivered. This review seeks to provide a comprehensive understanding of how IoT enables real-time monitoring and predictive maintenance, how AI drives automation and decision-making, and how big data analytics enhances process optimization and quality control. By exploring these advancements, the review will highlight how these technologies improve efficiency, reduce costs, ensure product quality, and pave the way for more personalized and responsive pharmaceutical production. The review

also aims to address the challenges and limitations associated with the adoption of these technologies, providing insights into the future directions of digital transformation in the pharmaceutical industry.

3. Industry 4.0 and Its Relevance to Pharma Manufacturing

Definition and Components of Industry 4.0

Industry 4.0, often referred to as the fourth industrial revolution, represents the integration of digital technologies with traditional manufacturing processes to create highly automated, data-driven, and interconnected production environments known as "smart factories." The key components of Industry 4.0 include [7-10]:

- **Smart Factories:** These are manufacturing environments where machinery and systems are interconnected through IoT, allowing them to communicate, monitor, and optimize production processes in real time. Smart factories utilize data analytics to make autonomous decisions, improving efficiency and reducing downtime.
- **Cyber-Physical Systems:** These systems bridge the physical and digital worlds by integrating physical processes with computer-based algorithms. In pharma manufacturing, cyber-physical systems enable real-time monitoring, simulation, and control of production processes, leading to greater precision and flexibility.
- **Automation:** Automation under Industry 4.0 involves using robotics, AI, and machine learning to perform tasks previously done manually. This includes everything from automated quality control and packaging to predictive maintenance and inventory management, significantly enhancing productivity and reducing human error.

The Need for Digital Transformation in Pharma

Traditional pharmaceutical manufacturing faces numerous challenges, including inefficiencies, high costs, and complexities in ensuring consistent product quality. The strict regulatory requirements and the need for extensive documentation and compliance exacerbate these challenges [11, 12].

Table 2: Challenges and addresses in traditional Pharmaceutical Manufacturing

Challenges in Traditional Pharma Manufacturing	How Industry 4.0 Addresses These Challenges
Inefficiency	Efficiency: Industry 4.0 enhances efficiency through automation and real-time data analytics, allowing for faster, more accurate production processes with reduced waste.
Complexity	Quality Control: By integrating IoT and AI, Industry 4.0 enables continuous monitoring and

	control of quality throughout the production process, ensuring consistent standards and reducing recalls.
Regulatory Compliance	Regulatory Compliance: Digitalization of processes under Industry 4.0 allows for automated documentation and reporting, ensuring easier compliance with regulations and minimizing human error.

4. The Role of IoT in Pharma Manufacturing

IoT-Enabled Smart Manufacturing

The Internet of Things (IoT) is pivotal in enabling smart manufacturing within the pharmaceutical industry. IoT involves the use of sensors, connected devices, and real-time data collection to create an interconnected production environment. In pharma manufacturing, IoT sensors are deployed across various stages of the production process, from raw material handling to packaging. These sensors continuously monitor critical parameters such as temperature, humidity, pressure, and machine performance, providing real-time data for maintaining optimal production conditions. Connected devices can communicate with each other and central systems, enabling automated adjustments and immediate responses to deviations from the desired conditions. This level of connectivity ensures a higher degree of precision, reduces the risk of human error, and enhances the overall efficiency of manufacturing operations [13, 14].

Process Optimization and Monitoring

IoT significantly improves process optimization and monitoring in pharmaceutical manufacturing. By collecting and analyzing real-time data from various stages of production, IoT systems can identify inefficiencies, predict potential issues, and optimize workflows. For instance, IoT-enabled predictive maintenance uses data from equipment sensors to forecast when a machine is likely to fail, allowing for proactive maintenance before a breakdown occurs. This reduces unplanned downtime, minimizes repair costs, and maintains production schedules [15]. Furthermore, IoT allows for continuous process monitoring, enabling real-time adjustments to maintain product quality and consistency. This level of oversight is crucial in an industry where precision and reliability are paramount [16].

Enhancing Supply Chain Management

IoT also enhances supply chain management by providing real-time tracking and visibility of raw materials and finished products throughout the supply chain. IoT devices, such as RFID tags and GPS trackers, can monitor the location, condition, and movement of materials as they travel through the supply chain. This real-time tracking ensures that raw materials arrive on time and in the correct condition, reducing the risk of delays or quality issues. IoT enables manufacturers to track their

journey from the factory to the end-user for finished products, ensuring that products are stored and transported under optimal conditions. This supply chain transparency helps maintain pharmaceutical products' integrity, improving inventory management and ensuring that products reach patients safely and efficiently [17,18].

Table 3: summarising the role of IoT in pharmaceutical manufacturing:

Aspect	Description
IoT-Enabled Smart Manufacturing	IoT integrates sensors and connected devices across the production process to monitor critical parameters (e.g., temperature, humidity, and pressure) in real time, enhancing precision, reducing errors, and improving efficiency.
Process Optimization and Monitoring	IoT systems collect and analyze real-time data to identify inefficiencies, predict potential issues, and optimize workflows, including predictive maintenance to reduce downtime and maintain production schedules.
Enhancing Supply Chain Management	IoT provides real-time tracking of raw materials and finished products using RFID tags and GPS, ensuring timely and optimal condition delivery, improving inventory management, and maintaining product integrity.

5. The Impact of AI in Pharmaceutical Manufacturing

AI in Drug Discovery and Development

Artificial Intelligence (AI) is revolutionizing drug discovery and development by significantly accelerating the process through predictive modelling and simulations. Traditionally, drug discovery is a time-consuming and costly endeavour involving extensive trial-and-error testing of compounds. AI changes this paradigm by using machine learning algorithms to analyze vast datasets of biological and chemical information, identifying potential drug candidates more quickly and accurately [18]. Predictive modelling allows AI to simulate how different compounds interact with biological targets, predicting their efficacy and potential side effects before they reach the laboratory stage. This capability shortens the drug development timeline, reduces costs, and increases the likelihood of success, enabling pharmaceutical companies to bring new therapies to market faster and more efficiently [19-21].

Process Automation and Quality Control

In pharmaceutical manufacturing, AI-driven automation plays a crucial role in enhancing precision and reducing errors throughout the production process. AI algorithms can monitor and control manufacturing operations in real time, adjusting parameters such as temperature, pressure, and flow rates to maintain optimal conditions. This level of automation ensures consistent product quality and minimizes the risk of human error, which is critical in an industry where precision is paramount. Moreover, AI systems can automatically detect deviations from the set standards and initiate corrective actions, further safeguarding product quality. In quality control, AI-powered image recognition and analysis can inspect products at a microscopic level, identifying defects or inconsistencies that human inspectors might miss. This leads to higher product reliability and compliance with stringent regulatory requirements [22, 23].

Predictive Analytics for Maintenance and Process Improvement

AI's predictive analytics application transforms maintenance and process improvement in pharmaceutical manufacturing. Predictive analytics involves using AI to analyse historical and real-time data from manufacturing equipment to predict when a machine is likely to fail. By identifying patterns and anomalies in equipment performance, AI can forecast potential issues before they result in costly breakdowns or production stoppages. This allows for scheduled maintenance to be performed at the most opportune times, reducing unplanned downtime and extending the lifespan of machinery. Additionally, AI can optimize production processes by continuously analyzing data to identify inefficiencies and recommend adjustments. This leads to improved productivity, lower operating costs, and enhanced efficiency in pharmaceutical manufacturing operations [24,25].

6. Big Data and Its Applications in Pharma Manufacturing

Data-Driven Decision Making

Big data is transforming pharmaceutical manufacturing by enabling data-driven decision-making across all stages of the production process. With the vast amounts of data generated from sensors, machines, and quality control systems, manufacturers can leverage big data analytics to gain deeper insights into their operations. By analyzing historical and real-time data, companies can identify patterns, trends, and correlations that inform critical decisions, such as optimizing production schedules, improving process efficiency, and reducing costs. [26] For example, big data can help manufacturers predict demand fluctuations, adjust production volumes accordingly, and allocate resources more effectively. This data-driven approach ensures that decisions are based on accurate, comprehensive information, leading to more efficient and agile manufacturing processes [27].

Quality Assurance and Compliance

Quality assurance and regulatory compliance are paramount in the highly regulated pharmaceutical industry. Big data is crucial in ensuring that manufacturing processes adhere to strict regulatory standards. Big data analytics can detect deviations from established quality parameters in real time by continuously monitoring and analyzing data from production lines. This allows immediate corrective actions, ensuring all products meet the required specifications. Furthermore, big data facilitates traceability, enabling manufacturers to track the entire lifecycle of a product, from raw materials to finished goods [28]. This traceability is essential for compliance with regulatory requirements, such as those set by the FDA and EMA, as it provides a comprehensive record of production processes that can be audited and verified. In the event of a recall or investigation, big data ensures that manufacturers can quickly identify the source of any issues and respond appropriately [29].

Personalization and Customized Production

Big data also drives the shift toward personalized medicine and customized drug production. As the demand for personalized treatments grows, pharmaceutical manufacturers must adapt their processes to produce drugs tailored to individual patient needs. Big data enables this by analyzing patient-specific information, such as genetic profiles, medical histories, and treatment responses, to guide the production of customized therapies. For example, big data can help determine each patient's optimal dosage, formulation, and delivery method, ensuring the treatment is as effective as possible [30]. Additionally, big data supports manufacturing small batches of customized drugs, making it feasible to produce personalized medicine on a larger scale. This level of customization improves patient outcomes and represents a significant advancement in how pharmaceutical products are developed and manufactured [31].

7. Case Studies and Real-World Applications

Successful Implementation of IoT, AI, and Big Data

Several pharmaceutical companies have successfully implemented IoT, AI, and big data to transform their manufacturing processes, leading to significant improvements in efficiency, quality, and innovation [32-34].

- **GSK (GlaxoSmithKline):** GSK has leveraged IoT and big data to enhance its manufacturing processes. By integrating IoT sensors across its production lines, GSK can monitor and control environmental conditions in real time, ensuring consistent product quality. The data collected is analyzed using AI algorithms to optimize production schedules, predict maintenance needs, and reduce downtime, resulting in more efficient and reliable manufacturing operations.

- Pfizer:** Pfizer has embraced AI and big data in its drug development and manufacturing processes. The company uses AI-driven predictive modeling to accelerate drug discovery, reducing the time it takes to bring new drugs to market. Additionally, Pfizer employs big data analytics to optimize its supply chain, ensuring that materials are delivered on time and that production schedules are aligned with demand forecasts. This integration of AI and big data has allowed Pfizer to streamline its operations and improve its responsiveness to market changes.
- Novartis:** Novartis has implemented AI and IoT technologies to create a "smart factory" environment. By using AI for predictive maintenance and process optimisation, Novartis has reduced production costs and increased operational efficiency. The company also uses IoT devices to monitor production conditions and ensure compliance with regulatory standards. This digital transformation has positioned Novartis as a leader in adopting advanced technologies in pharmaceutical manufacturing.

Table 4: Summarizing the case studies and real-world applications of IoT, AI, and Big Data in pharmaceutical manufacturing:

Company	Technologies Implemented	Applications	Outcomes
GSK (GlaxoSmith Kline)	IoT, Big Data, AI	Integrated IoT sensors across production lines to monitor and control environmental conditions in real-time. Used AI algorithms to analyze data for optimizing production schedules, predicting maintenance needs, and reducing downtime.	Enhanced manufacturing efficiency, consistent product quality, reduced downtime.
Pfizer	AI, Big Data	Employed AI-driven predictive modeling in drug development to accelerate drug discovery. Used big data analytics to optimize supply chain, ensuring timely material delivery and aligning production schedules with demand forecasts.	Streamlined operations, faster drug discovery, improved responsiveness to market changes.
Novartis	AI, IoT	Created a "smart factory" environment using AI for predictive maintenance and process optimization. Utilized IoT devices to monitor production conditions and ensure regulatory compliance.	Reduced production costs, increased operational efficiency, leadership in digital transformation.

Lessons Learned and Best Practices

The successful implementation of IoT, AI, and big data in pharmaceutical manufacturing offers valuable lessons and best practices that can guide other companies in their digital transformation journeys [35-37].

- Start with a Clear Strategy:** Companies that have successfully integrated these technologies started with a clear digital transformation strategy. This strategy should align with the company's overall goals and include a roadmap for implementing IoT, AI, and big data technologies. It's essential to prioritize initiatives with the greatest potential for improving efficiency, quality, and compliance.
- Invest in Infrastructure:** A robust IT infrastructure is critical for supporting the deployment of IoT, AI, and big data. Companies must ensure they have the necessary hardware, software, and data storage capabilities to handle the large volumes of data generated by these technologies. Additionally, cyber security measures must be in place to protect sensitive data and ensure regulatory compliance.
- Focus on Change Management:** Digital transformation requires significant changes in how employees work and manage processes. Successful companies invest in change management programs to ensure employees are trained and prepared to work with new technologies. This includes fostering a

culture of innovation and encouraging collaboration between IT and operational teams.

- Adopt a Data-Driven Approach:** Companies that leverage big data effectively use it to inform decision-making at all levels of the organization. This involves developing the capability to analyze data in real time and integrating data analytics into everyday business processes. By adopting a data-driven approach, companies can make more informed decisions, optimize operations, and respond quickly to changing market conditions.
- Collaborate with Technology Partners:** Partnering with technology providers and experts is a best practice that has helped pharmaceutical companies navigate the complexities of implementing IoT, AI, and big data. These partnerships provide access to the latest technologies and expertise, enabling companies to overcome technical challenges and accelerate their digital transformation.

Table 5: Summarizing the lessons learned and best practices for implementing IoT, AI, and Big Data in pharmaceutical manufacturing:

Lesson/Best Practice	Description
Start with a Clear Strategy	Develop a digital transformation strategy aligned with the company's overall goals. Create a roadmap for implementing IoT, AI, and big data technologies,

	prioritizing initiatives with the highest potential impact.
Invest in Infrastructure	Ensure a robust IT infrastructure is in place, including necessary hardware, software, and data storage capabilities. Implement cyber security measures to protect sensitive data and ensure regulatory compliance.
Focus on Change Management	Invest in change management programs to train employees and prepare them for new technologies. Foster a culture of innovation and encourage collaboration between IT and operational teams.
Adopt a Data-Driven Approach	Leverage big data to inform decision-making at all levels of the organization. Develop real-time data analysis capabilities and integrate data analytics into daily business processes.
Collaborate with Technology Partners	Partner with technology providers and experts to access the latest technologies and expertise. These collaborations help navigate technical challenges and accelerate digital transformation.

8. Challenges and Limitations

Integration Challenges

One of the significant hurdles in adopting IoT, AI, and big data in pharmaceutical manufacturing is the difficulty of integrating these advanced technologies into existing operations. Pharmaceutical companies often rely on legacy systems and infrastructure not designed to accommodate the seamless connectivity and data flow required by IoT and AI applications. Integrating new technologies with these outdated systems can be complex, requiring significant upgrades, custom solutions, and substantial investment. Moreover, the integration process can disrupt existing workflows and operations, leading to potential downtime and increased operational risks [38]. Companies must also ensure that their workforce is adequately trained to work with these new technologies, which can be time-consuming and resource-intensive. Overall, the integration of IoT, AI, and big data into established pharma operations is a challenging but necessary step for companies aiming to modernise their production capabilities [39-42].

Data Security and Privacy Concerns

As pharmaceutical companies increasingly rely on IoT, AI, and big data, they face heightened data security and privacy risks. The integration of connected devices and the generation of vast amounts of data create more entry points for cyberattacks, making pharmaceutical companies prime targets for hackers. Breaches in data security can lead to the theft of sensitive intellectual property, patient data, and proprietary information, resulting in significant financial losses and damage to a

company's reputation [40]. Moreover, the pharmaceutical industry is subject to stringent data privacy regulations, such as GDPR in Europe and HIPAA in the United States, which mandate strict controls over personal data collection, storage, and processing. Ensuring compliance with these regulations while implementing advanced digital tools requires robust cybersecurity measures, continuous monitoring, and regular audits to protect sensitive data from unauthorized access and breaches [43].

Regulatory and Compliance Issues

Navigating the regulatory landscape is another major challenge in the digital transformation of pharmaceutical manufacturing. The pharmaceutical industry is one of the most heavily regulated sectors, with strict guidelines governing every aspect of drug development, manufacturing, and distribution. The adoption of IoT, AI, and big data introduces new complexities in ensuring compliance with these regulations. For instance, regulatory bodies like the FDA require extensive documentation and validation of manufacturing processes to ensure product quality and safety. Digital tools must be thoroughly validated and documented to demonstrate their reliability and accuracy, which can be time-consuming and expensive. Additionally, regulations are still evolving to keep pace with technological advancements, creating uncertainty for companies adopting these new tools. Pharma companies must work closely with regulatory agencies to navigate these challenges, ensuring that their use of digital technologies complies with existing regulations while anticipating future changes [44-46].

9. Future Directions

As digital technologies evolve, their role in pharmaceutical manufacturing is expected to expand, driving further advancements and transforming the industry. Future developments in IoT, AI, and big data will likely lead to even greater precision, efficiency, and customization in drug production. Emerging technologies such as quantum computing, advanced machine learning algorithms, and more sophisticated IoT devices could further optimize drug discovery, manufacturing, and supply chain management. These advancements are expected to reduce production times, lower costs, and enable the creation of more personalized medicines tailored to individual patient needs. Additionally, the increased use of digital twins—virtual models of physical processes—could allow for real-time simulations and adjustments, enhancing process control and product quality.

The shift toward fully automated and autonomous pharmaceutical manufacturing represents a significant future direction for the industry. Building on the foundation of smart factories, where machines and systems are interconnected and capable of making real-time adjustments, the next step is the development of fully autonomous facilities. In these environments, AI-

driven systems will manage the entire production process, from raw material procurement to final product distribution, with minimal human intervention. This transition will require significant advancements in robotics, AI, and machine learning, as well as robust cyber security measures to protect these autonomous systems. Achieving this level of automation will also necessitate strong collaborations and ecosystem development, with partnerships between tech companies, pharmaceutical manufacturers, and regulators playing a critical role. These collaborations will be essential for developing and implementing the standards, technologies, and regulatory frameworks needed to support the safe and effective deployment of fully autonomous pharmaceutical manufacturing.

10. Conclusion

The integration of digital technologies like IoT, AI, and big data is revolutionizing pharmaceutical manufacturing by driving efficiency, enhancing quality control, and ensuring regulatory compliance. Industry 4.0, characterized by smart factories and cyber-physical systems, enables real-time monitoring, predictive maintenance, and automated decision-making, addressing challenges such as inefficiencies, high costs, and regulatory complexities. IoT facilitates real-time data collection and process optimization, AI enhances drug discovery, automation, and quality control, while big data supports data-driven decision-making and personalized medicine. Despite challenges in system integration, data security, and regulatory compliance, the future of pharmaceutical manufacturing will be shaped by advancements like quantum computing and digital twins, moving towards fully autonomous facilities. Collaborative efforts between pharma companies, tech providers, and regulators will be key to realizing this vision.

Funding

No

Acknowledgement

Nil

Conflict of Interest

No conflict of interest.

Informed Consent

Not applicable.

Ethical Statement

Not applicable.

Author Contribution

Sanket J Soni, Ankitkumar N Patel both are contributed equally.

References

1. Lee J, Bagheri B, Kao HA. A cyber-physical systems architecture for Industry 4.0-based manufacturing systems. *Manuf Lett*. 2015 Jan 1;3:18-23.
2. Xu LD, Xu EL, Li L. Industry 4.0: state of the art and future trends. *Int J Prod Res*. 2018 Nov 17;56(8):2941-2962.
3. Wan J, Tang S, Li D, Wang S, Liu C, Abbas H, Vasilakos AV. A manufacturing big data solution for active preventive maintenance. *IEEE Trans Ind Inform*. 2017 Mar;13(4):2039-2047.
4. Qin J, Liu Y, Grosvenor R. A categorical framework of manufacturing for industry 4.0 and beyond. *Procedia CIRP*. 2016 Jan 1;52:173-178.
5. Thoben KD, Wiesner SA, Wuest T. "Industrie 4.0" and smart manufacturing—a review of research issues and application examples. *Int J Autom Technol*. 2017 Mar;11(1):4-16.
6. Schmitt R. Big data analytics for predictive maintenance strategies. *IFAC-PapersOnLine*. 2015 Dec 1;48(3):223-228.
7. Rößmann M, Lorenz M, Gerbert P, Waldner M, Justus J, Engel P, Harnisch M. Industry 4.0: The future of productivity and growth in manufacturing industries. Boston Consulting Group. 2015 Apr 9.
8. Davies R. Industry 4.0: Digitalisation for productivity and growth. European Parliament, Research Department. 2015 Sep 30.
9. Kagermann H, Hellwig J, Hellinger A, Wahlster W. Recommendations for implementing the strategic initiative INDUSTRIE 4.0: Securing the future of German manufacturing industry; final report of the Industrie 4.0 Working Group. *Forschungsunion*. 2013 Apr.
10. Rajput S, Singh SP. Industry 4.0—challenges to implement cyber-physical system in digitized manufacturing. *Procedia CIRP*. 2018 Jan 1;67:620-625.
11. Shrouf F, Ordieres-Meré J, García-Sánchez A, Ortega-Mier M. Optimizing the production scheduling of a single machine to minimize total energy consumption costs. *J Clean Prod*. 2014 Oct 1;67:197-207.
12. Monostori L, Kádár B, Bauernhansl T, Kondoh S, Kumara SR, Reinhart G, Sauer O, Schuh G, Sihn W, Ueda K. Cyber-physical systems in manufacturing. *CIRP Ann*. 2016 Jan 1;65(2):621-641.
13. Zhong RY, Xu X, Klotz E, Newman ST. Intelligent manufacturing in the context of Industry 4.0: a review. *Engineering*. 2017 Mar 1;3(5):616-630.
14. Bibby L, Dehe B. Defining and assessing industry 4.0 maturity levels—case of the defence sector. *Prod Plan Control*. 2018 May 4;29(12):1030-1043.
15. Wang K, Yu Y, Shen Y, Sun H. Big data analytics for systemic risk management in smart supply chains. *J SystSciSyst Eng*. 2018 Dec;27(6):715-736.
16. Heng S. Industry 4.0: Upgrading the manufacturing sector. *Deutsche Bank Research*. 2014 Nov 20.
17. Geissbauer R, Vedso J, Schrauf S. Industry 4.0: Building the digital enterprise. *PwC Report*. 2016.

18. Bagheri B, Yang S, Kao HA, Lee J. Cyber-physical systems architecture with cloud-based big data analytics for smart manufacturing. *Manufacturing letters*. 2015 Jan 1;3:18-23.
19. Gilchrist A. *Industry 4.0: The industrial internet of things*. Springer; 2016.
20. Ehret M, Wirtz J. Unlocking value from machines: business models and the industrial internet of things. *J Mark Manag*. 2017 Feb 7;33(1-2):111-130.
21. Schlechtendahl J, Keinert M, Kretschmer F, Lechler A, Verl A. Making existing production systems Industry 4.0-ready. *Prod Eng*. 2015 Feb;9(1):143-148.
22. Kolberg D, Zühlke D. Lean automation enabled by Industry 4.0 technologies. *IFAC-PapersOnLine*. 2015 Dec 1;48(3):1870-1875.
23. Yoon J, Pearson K, Garrison G, McMullen J, Kozlowski S. Data analytics in the context of data warehousing: a tutorial. *ACM J Data Inf Qual*. 2018 Mar 8;9(1):1-7.
24. Ferretti M, Schiavone F, Werth D, Monaca MA. Industrial smart working: how to generate digital innovation in operations. *J Bus Res*. 2020 May 1;112:373-384.
25. Mittal S, Khan MA, Romero D, Wuest T. A critical review of smart manufacturing & Industry 4.0 maturity models: implications for small and medium-sized enterprises (SMEs). *J Manuf Syst*. 2018 Oct 1;49:194-214.
26. Smit J, Kreutzer S, Moeller C, Carlberg M. *Industry 4.0: Study for the ITRE Committee*. European Parliament, Policy Department. 2016 Feb 23.
27. Chowdary KP, Chandra DU, Mahesh N, Reddy TM, Gopaiah KV. Enhancement of dissolution rate and formulation development of pioglitazone-a BCS class II drug. *J. Pharm. Res*. 2011 Nov;4:3862-3.
28. Kagermann H. Change through digitization—Value creation in the age of Industry 4.0. In *Management of permanent change 2015* (pp. 23-45). Springer, Cham.
29. Shrouf F, Ordieres JM, Miragliotta G. Smart factories in Industry 4.0: A review of the concept and of energy management approached in production based on the Internet of Things paradigm. *IEEE Trans Ind Inform*. 2014 Dec;10(4):362-370.
30. Bai C, Dallasega P, Orzes G, Sarkis J. Industry 4.0 technologies assessment: A sustainability perspective. *Int J Prod Econ*. 2020 Nov 1;229:107776.
31. Zawadzki P, Żywicki K. Smart product design and production control for effective mass customization in the Industry 4.0 concept. *Manag Prod Eng Rev*. 2016 Dec 1;7(3):105-112.
32. Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. *AAPS PharmSciTech* 19, 1358–1366 (2018).
33. Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. *Chromatographia* 80, 1211–1224 (2017).
34. Kakulamarrri PR, Alikatte KL, Mateti UV (2016) Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. *J Pharm Drug Deliv Res* 5:3
35. Kakullamarri PR, Rao KLN (2017) Enhanced Bioavailability and Anticancer Activity of Vitamin Analogs. *J BioequivAvailab* 9: 439-441.
36. Kumar KR, Nagaraju GV, Subrahmanyam SN, Nagarani K, Shareef S, Tennygilphin M, Namballa M. Assessment on Elements Involving the Academic Performance among Pharmacy Students: A Cross-Sectional Observational Study. *Int J Cur Res Rev* Vol. 2021 Dec;13(23):141.
37. Porter ME, Heppelmann JE. How smart, connected products are transforming competition. *Harv Bus Rev*. 2014 Nov;92(11):64-88.
38. Srai JS, Kumar M, Graham G, Phillips W, Tooze J, Ford S, Beecher P, Raj B, Gregory M, Tiwari MK, Ravi B, Neely A. Distributed manufacturing: scope, challenges and opportunities. *Int J Prod Res*. 2016 Nov 17;54(23):6917-6935.
39. Ray Y, Choudhary AK, Kumar V, Tiwari MK. Big data analytics for sustainability of manufacturing operations: An Industry 4.0 perspective. *J Clean Prod*. 2020 Dec 10;259:120776.
40. Modgil S, Gupta S, Sinha VK, Kansal M. Big data in lean six sigma: A review and further research directions. *Int J Prod Res*. 2020 Sep 30;58(18):5609-5630.
41. Kusiak A. Smart manufacturing. *Int J Prod Res*. 2018 Nov 17;56(1-2):508-517.
42. Lu Y. Industry 4.0: A survey on technologies, applications and open research issues. *J Ind InffIntegr*. 2017 Jun 1;6:1-10.
43. Turner RM, Bernard CD. Machine learning for analytics in industry 4.0: A scalable architecture for smart manufacturing. *J Manuf Syst*. 2020 Apr 1;54:75-84.
44. Sousa MJ, Rocha A. Digital learning: Developing skills for digital transformation of organizations. *Future Internet*. 2019 Mar 27;11(3):73.
45. Lu Y, Xu X. Cloud-based manufacturing equipment and big data analytics to enable on-demand manufacturing services. *Robot ComputIntegr Manuf*. 2019 Jun 1;57:92-102.
46. Hermann M, Pentek T, Otto B. Design principles for industrie 4.0 scenarios: A literature review. *Technol InnovManag Rev*. 2016 Jul 1;6(7):38-43.